GILD Gilead Sciences

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
Company profile
Ticker
GILD
Exchange
Website
CEO
Daniel O'Day
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
SEC CIK
Corporate docs
IRS number
943047598
GILD stock data
()
News
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
27 Feb 21
Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment
22 Feb 21
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
19 Feb 21
Gilead Sciences Reports New Partnership With Wake Forest University School Of Divinity To Address HIV Epidemic Through Faith-Based Programming and Community Outreach
16 Feb 21
10 Biggest Price Target Changes For Thursday
11 Feb 21
Press releases
Gilead Sciences to Present at Upcoming Investor Conferences
18 Feb 21
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
16 Feb 21
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
10 Feb 21
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
10 Feb 21
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
8 Feb 21
Calendar
25 Feb 21
28 Feb 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6B | 6B | 6B | 6B | 6B | 6B |
Cash burn (monthly) | 2.3B | 469.5M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 4.55B | 930.92M | n/a | n/a | n/a | n/a |
Cash remaining | 1.44B | 5.07B | n/a | n/a | n/a | n/a |
Runway (months of cash) | 0.6 | 10.8 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Feb 21 | Brett A Pletcher | Common Stock | Sell | Dispose S | No | Yes | 67.41 | 1,975 | 133.13K | 28,832 |
10 Feb 21 | Wilfong Diane E. | Common Stock | Payment of exercise | Dispose F | No | No | 67.29 | 197 | 13.26K | 17,409 |
10 Feb 21 | Wilfong Diane E. | Common Stock | Option exercise | Aquire M | No | No | 0 | 778 | 0 | 17,606 |
10 Feb 21 | Wilfong Diane E. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 778 | 0 | 15,327 |
6 Feb 21 | Dickinson Andrew D | Common Stock | Payment of exercise | Dispose F | No | No | 68.46 | 538 | 36.83K | 32,543 |
6 Feb 21 | Dickinson Andrew D | Common Stock | Option exercise | Aquire M | No | No | 0 | 1,818 | 0 | 33,081 |
6 Feb 21 | Dickinson Andrew D | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,818 | 0 | 30,300 |
6 Feb 21 | Brett A Pletcher | Common Stock | Payment of exercise | Dispose F | No | No | 68.46 | 753 | 51.55K | 30,807 |
6 Feb 21 | Brett A Pletcher | Common Stock | Option exercise | Aquire M | No | No | 0 | 2,728 | 0 | 31,560 |
6 Feb 21 | Brett A Pletcher | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,728 | 0 | 15,824 |
Institutional ownership Q4 2020
76.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1475 |
Opened positions | 179 |
Closed positions | 203 |
Increased positions | 490 |
Reduced positions | 663 |
13F shares |
Current |
---|---|
Total value | 55.92B |
Total shares | 952.21M |
Total puts | 25.87M |
Total calls | 20.87M |
Total put/call ratio | 1.2 |
Largest owners |
Shares | Value |
---|---|---|
Capital Research Global Investors | 121.67M | $7.09B |
BLK Blackrock | 111.18M | $6.48B |
Vanguard | 102.79M | $5.99B |
STT State Street | 55.21M | $3.22B |
Capital International Investors | 46.55M | $2.71B |
Capital World Investors | 38.53M | $2.24B |
Geode Capital Management | 20.08M | $1.17B |
Dodge & Cox | 17.11M | $996.71M |
NTRS Northern Trust | 15.24M | $888.11M |
BK Bank Of New York Mellon | 13.81M | $804.37M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accredited, ADC, Advisor, advocacy, affiliate, aim, airline, ambition, amid, amplify, Anthony, ASCENT, Asian, assumption, asterisk, autoleucel, barton, biased, Biochemistry, biology, BLA, Black, bluestone, breast, brexucabtagene, Bruton, built, bulevirtide, Cabaret, career, categorized, ceased, celebrate, chaired, Chapter, chargeback, childcare, clear, college, color, comprised, concentrated, conditionally, confirmatory, conjugate, constitute, constituted, constrain, consultation, Consummation, contemplated, contemplating, content, costly, Council, CTA, cultivate, curative, DaVita, deconsolidated, deconsolidation, dedicated, demurrer, diane, digit, disability, distancing, Divinity, Dr, duly, dynamic, earliest, EC, embedded, enjoined, EP, epidermal, equitable, ESG, Eshhar, essential, ethnic, evasion, EVG, evolution, exhibit, family, faster, feedback, female, Fire, Forest, formatted, Forty, freight, gender, genetic, Glaxo, GmbH, gradual, graduate, Grantee, greatest, Gritstone, GTN, HDV, healthier, hepcludex, herewith, Hetero, Hispanic, home, hormone, horning, HR, hub, ICH, Indemnity, inflation, Inline, instance, investor, IOCB, irrevocably, ISABELA, Jacksonville, jacqueline, javier, jeffrey, JMHLW, job, Jounce, jurisdiction, jyseleca, kelly, kevin, KR, kramer, lag, lawfully, lenacapavir, lesser, letter, lieu, lifesaving, Linkbase, listening, lofton, Los, lung, magrolimab, male, Mateo, Mayor, MDS, meaningful, medium, merged, merger, metastatic, misalignment, mission, Missouri, mobilization, moderate, moderately, monthly, morale, mTNBC, myelodysplastic, myeloid, MYR, nonprofit, Nonstatutory, notification, NSCLC, objective, occupancy, omitted, onsite, opt, orientation, Orphan, outbound, outbreak, outpatient, overruled, overruling, pandemic, pathway, pause, physical, physically, Pionyr, Police, postponement, prejudgment, PRIME, race, racial, rapid, ratifying, real, reconfiguration, referenced, refiled, rega, religion, rendered, reoccur, repay, resubstitution, retaliation, reward, richard, RNA, Rodino, rodriguez, route, RPI, sacituzumab, salary, sandra, satisfaction, sBLA, Schema, scheme, School, science, seal, secondary, sense, shelter, signature, Sonoma, split, stead, Stichting, stream, substance, substantive, substitute, substitution, successor, surge, surrogacy, talent, talented, Taxonomy, tecartustm, thereto, thereunto, therewith, thing, thousand, tightened, Title, Tizona, TMFPA, tooth, topoisomerase, tracing, travel, Triangle, tribunal, trodelvy, true, Trustee, TSR, tuition, twelve, tyrosine, unanticipated, unchanged, unconditional, undergraduate, undersigned, unemployment, UnitedHealth, unlawful, Unlimited, unrelated, urgency, urothelial, valuable, variation, veklury, verification, veteran, vi, vii, Vir, virtue, waiting, Wake, Wellcome, whitley, wilfong, willingly, women, workforce, XBRL, Zelig
Removed:
AbbVie, absence, ACC, accelerate, accept, advanced, Alameda, allegedly, American, backlog, batch, bill, body, cellular, China, clarification, contamination, copay, cure, Daiichi, deem, discontinuance, DNA, donation, doubtful, elimination, exclude, expedited, explanation, finalization, fit, forming, formulary, governor, harvesting, HIPAA, historically, impair, improving, indefinitely, ingredient, injured, IRS, lessen, LIBOR, limiting, locate, mab, MAGE, magnified, materialize, maturation, Merck, MINE, myeloma, narrow, NASH, neutralizing, nonalcoholic, participating, planned, practical, preceding, produce, prosecution, prospective, provisional, qualify, QUALITATIVE, recruitment, refer, reject, remanded, repatriated, repeal, replaced, replacement, reputational, revision, safer, Sankyo, schedule, selonsertib, sex, stay, suffer, tender, territorial, transparency, Trump, turn, UNRESOLVED, usage, USPTO, vivo, Watson, Writ
Financial reports
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
3 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K/A
2018 FY
Annual report (amended)
17 Apr 19
10-K
2018 FY
Annual report
25 Feb 19
Current reports
8-K
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
4 Feb 21
8-K
Gilead Sciences Announces Updated 2020 Guidance
11 Jan 21
8-K/A
Completion of Acquisition or Disposition of Assets
6 Jan 21
8-K
Jeffrey a. Bluestone Joins Gilead Sciences’ Board of Directors
8 Dec 20
8-K
Gilead Sciences Announces Third Quarter 2020 Financial Results
28 Oct 20
8-K
Completion of Acquisition or Disposition of Assets
23 Oct 20
8-K
Anthony Welters Joins Gilead Sciences’ Board of Directors
22 Oct 20
8-K
Entry into a Material Definitive Agreement
30 Sep 20
8-K
Entry into a Material Definitive Agreement
29 Sep 20
8-K
Gilead Sciences to Acquire Immunomedics
14 Sep 20
Registration and prospectus
S-8
Registration of securities for employees
3 Nov 20
SC TO-T/A
Third party tender offer statement (amended)
23 Oct 20
SC TO-T/A
Third party tender offer statement (amended)
14 Oct 20
SC TO-T/A
Third party tender offer statement (amended)
13 Oct 20
SC TO-T/A
Third party tender offer statement (amended)
2 Oct 20
424B5
Prospectus supplement for primary offering
25 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
25 Sep 20
SC TO-T
Third party tender offer statement
24 Sep 20
SC TO-C
Information about tender offer
24 Sep 20
FWP
Free writing prospectus
24 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
15 Apr 20
PX14A6G
Letter to shareholders
25 Mar 20
DEFA14A
Additional proxy soliciting materials
24 Mar 20
DEF 14A
Definitive proxy
24 Mar 20
DEFA14A
Additional proxy soliciting materials
25 Mar 19
DEF 14A
Definitive proxy
25 Mar 19
PRE 14A
Preliminary proxy
15 Mar 19
DEF 14A
Definitive proxy
25 Mar 18
DEFA14A
Additional proxy soliciting materials
25 Mar 18
DEF 14A
Definitive proxy
26 Mar 17
Other
CORRESP
Correspondence with SEC
1 Oct 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
14 Apr 20
CT ORDER
Confidential treatment order
28 Jan 20
CT ORDER
Confidential treatment order
12 Jul 19
CT ORDER
Confidential treatment order
12 Jul 19
CT ORDER
Confidential treatment order
7 Jun 19
CT ORDER
Confidential treatment order
21 Feb 19
CT ORDER
Confidential treatment order
12 Nov 18
Ownership
SC 13G/A
GILEAD SCIENCES / Capital Research Global Investors ownership change
16 Feb 21
SC 13G/A
GILEAD SCIENCES / Capital Research Global Investors ownership change
16 Feb 21
SC 13G/A
HOOKIPA Pharma / GILEAD SCIENCES ownership change
12 Feb 21
4
GILEAD SCIENCES / Diane E. Wilfong ownership change
11 Feb 21
4
GILEAD SCIENCES / Brett A Pletcher ownership change
11 Feb 21
SC 13G/A
GILEAD SCIENCES / VANGUARD ownership change
10 Feb 21
4
GILEAD SCIENCES / Diane E. Wilfong ownership change
9 Feb 21
4
GILEAD SCIENCES / Brett A Pletcher ownership change
9 Feb 21
4
GILEAD SCIENCES / Andrew D Dickinson ownership change
9 Feb 21
4
GILEAD SCIENCES / Brett A Pletcher ownership change
3 Feb 21
Patents
APP
Utility
Therapeutic Compositions for Treatment of Human Immunodeficiency Virus
25 Feb 21
A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
APP
Utility
PD-1/PD-L1 Inhibitors
25 Feb 21
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
APP
Utility
Methods for Treating Filoviridae Virus Infections
25 Feb 21
Inventors: Byoung Kwon Chun, Michael O' Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
APP
Utility
Compounds for Inhibition of Alpha 4 Beta 7 Integrin
25 Feb 21
Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Jason K. Perry, Natalie Seeger, Kirk L. Stevens, Zhongdong Zhao
APP
Utility
Antiviral Compounds
25 Feb 21
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Transcripts
2020 Q4
Earnings call transcript
5 Feb 21
2020 Q3
Earnings call transcript
28 Oct 20
2020 Q2
Earnings call transcript
30 Jul 20
2020 Q1
Earnings call transcript
30 Apr 20
2019 Q4
Earnings call transcript
4 Feb 20
2019 Q3
Earnings call transcript
24 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
4 Feb 19
2018 Q3
Earnings call transcript
25 Oct 18
Reddit threads
What caused stocks to dump yesterday: the unwinding of $50B worth of bonds
26 Feb 21
Best dividend value stocks to buy and go long.
25 Feb 21
What is a reasonable amount in dividends to expect from a 10k portfolio?
25 Feb 21
Undervalued high dividend yields
25 Feb 21
Do you plan to buy anything today?
22 Feb 21
We may be looking at a bearish week for Apple
21 Feb 21
BioCryst Short-Sellers Lose Control
21 Feb 21
ANY THOUGHTS ON STOCKS IN A DIP RIGHT NOW ?
20 Feb 21
Vlad's testimony in a nutshell
19 Feb 21
stocks I like - for the hedge funds buying tech to track this
19 Feb 21